Alzheimer's biotech comes under attack as petition calls for trial halt, data audit — and it's fighting back
Little Cassava Sciences has complete faith in its experimental Alzheimer’s drug. Ever since pivoting away from a four-time reject analgesic (and from its former identity as Pain Therapeutics), the biotech has plowed steadily away at clinical trials for a new lead program called simufilam, plotting major Phase III trials and significant investment into the neurodegenerative disease — even before the FDA approval of Biogen’s Aduhelm reinvigorated the entire field.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.